中超控股(002471) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥1,464,732,365.57, representing a decrease of 7.92% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥3,815,786.89, down 65.23% year-on-year, while the net profit excluding non-recurring gains and losses was ¥2,432,753.74, a decrease of 58.15%[5]. - The basic earnings per share for Q3 2023 was ¥0.0030, a decline of 65.41% compared to the same period last year[5]. - Total operating revenue for Q3 2023 reached CNY 4,241,142,671.71, a slight increase from CNY 4,204,561,737.72 in Q3 2022[20]. - Total operating costs for Q3 2023 were CNY 4,246,908,394.17, compared to CNY 4,213,889,867.40 in the same period last year[20]. - Net profit for Q3 2023 was CNY 250,095,430.13, a significant recovery from a net loss of CNY 30,761,928.15 in Q3 2022[22]. - The total comprehensive income for Q3 2023 was CNY 260,677,357.00, a recovery from a loss of CNY 20,039,615.25 in the same quarter last year[22]. - Basic and diluted earnings per share improved to CNY 0.1981, up from a loss of CNY -0.0236 in the previous year[23]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,620,242,381.68, a decrease of 0.75% from the end of the previous year[5]. - The company's total assets as of Q3 2023 amounted to CNY 5,620,242,381.68, slightly down from CNY 5,662,917,793.93 at the end of Q2 2023[19]. - Total liabilities decreased to CNY 3,949,300,760.70 in Q3 2023 from CNY 4,259,470,283.08 in Q2 2023[19]. - The company's equity attributable to shareholders increased to CNY 1,633,289,666.02 in Q3 2023, up from CNY 1,369,653,025.49 in Q3 2022[19]. Cash Flow - The company experienced a decrease in cash flow from operating activities, with a net cash outflow of ¥89,989,584.84, representing a decline of 141.35% year-to-date[5]. - The net cash flow from operating activities was negative at CNY -89,989,584.84, compared to a positive CNY 217,654,740.92 in the same period last year[23]. - The net cash flow from investing activities was CNY 24,771,093.50, down from CNY 71,655,812.09 in the previous year[24]. - The net cash flow from financing activities was CNY 92,058,244.07, a turnaround from a negative cash flow of CNY -268,616,174.25 in the same quarter last year[24]. - Total cash inflow from financing activities was CNY 2,326,839,429.54, compared to CNY 2,660,879,275.70 in the previous year[24]. Inventory and Assets Management - The company reported a significant increase in inventory, with a year-to-date increase of ¥185,764,871.25, or 33.70%, due to strong production and sales activity[8]. - The company recorded a substantial increase in other non-current assets, which rose by ¥35,200,658.97, or 184.05%, primarily due to an increase in contract assets aged over one year[8]. - Cash and cash equivalents as of September 30, 2023, amount to ¥658,973,075.02, down from ¥804,578,196.44 at the beginning of the year[17]. - Accounts receivable stands at ¥2,529,995,343.12, slightly decreased from ¥2,565,109,370.73 at the start of the year[17]. - Inventory increased to ¥737,012,114.07 from ¥551,247,242.82 at the beginning of the year, indicating a growth in stock levels[17]. - Total current assets decreased to ¥4,284,927,304.55 from ¥4,339,146,674.21 since the start of the year[17]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 91,426[13]. - Jiangsu Zhongchao Investment Group Co., Ltd. holds 17.39% of shares, totaling 220,444,030 shares[13]. - The top ten shareholders include individuals and institutions, with significant holdings by Jiangsu Zhongchao Investment Group and others[13]. - The company has no preferred shareholders as per the latest report[14]. Other Information - The company has completed the deregistration of its wholly-owned subsidiary, Jiangsu Zhongchao Medical Health Investment Management Co., Ltd.[15]. - The company has decided to terminate the establishment of a healthcare industry fund with Su Min Investment Management Wuxi Co., Ltd.[16]. - Research and development expenses for Q3 2023 were CNY 148,998,424.78, compared to CNY 144,834,601.67 in Q3 2022, indicating continued investment in innovation[20]. - The company reported a significant increase in other income, totaling CNY 273,867,983.67 in Q3 2023, compared to CNY 3,277,194.54 in Q3 2022[22]. - The report was not audited, indicating that the figures may be subject to change upon final review[25].